Cofactor Genomics
Cofactor Genomics is a St. Louis-based diagnostics company that develops RNA-based tests to predict cancer immunotherapy response.
Competitive Advantages
Cofactor Genomics differentiates on multidimensional RNA biomarkers that model the tumor immune microenvironment, rather than relying on a single analyte such as PD-L1 expression. Its tests are being evaluated in the multi-system PREDAPT trial, which spans many health systems and solid tumor types.
National Medicare coverage through Palmetto GBA gives the OncoPrism tests a reimbursement footing that many novel diagnostics lack. The company also holds US patent protection around its immune-profiling approach, including patent publication 20200227138.
Source: cofactorgenomics.com
Market Outlook
Cofactor Genomics is expanding evidence for its tests through the PREDAPT study, which enrolls patients across more than two dozen health systems and eleven solid tumor types. Broader validation across tumor types could widen the addressable use of RNA-based response prediction.
Commercial growth depends on a partnered-hospital rollout and continued payer acceptance beyond the existing national Medicare coverage. An advisory network of oncology opinion leaders supports clinical adoption as immunotherapy use keeps growing.
Source: cofactorgenomics.com
Product Overview
Cofactor Genomics offers the OncoPrism family of RNA-based tests that predict solid-tumor response to immunotherapy, including versions for recurrent or metastatic head and neck squamous cell carcinoma and for non-small cell lung cancer. The tests run in the company CLIA high-complexity laboratory with a turnaround of about two weeks and are covered nationally by Medicare through Palmetto GBA.
The assays are laboratory-developed tests and are not FDA cleared. Ordering runs through the company requisition process with results reported as response likelihood scores that treating physicians use alongside clinical judgment.
Source: cofactorgenomics.com